Manas Kumar Behera
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Manas Kumar Behera has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Girish Kumar Pati
Professor, Department of Gastroenterology, Institute of Medical Sciences and Sum Hospital, Bhubaneswar, India
2 shared publications - Jimmy Narayan
Department of Gastroenterology, Institute of Medical Sciences and SUM Hospital, Bhubaneswar, India
2 shared publications - Ayaskanta Singh
SUM Ultimate Medicare, Bhubaneswar, India
1 shared publication Chinmayee Kar
IMS and SUM Hospital; Bhubaneswar, Odisha, India
1 shared publication- Debakanta Mishra
Department of Gastroenterology and Hepatobiliary Sciences, IMS and SUM Hospital, Siksha 'O' Anusandhan University, Bhubaneswar, Odisha, India
1 shared publication - Kanishka Uthansingh
Multi-Speciality Research Unit, KIMS Cancer Center, KIMS Hospital, KIIT University
1 shared publication
Latest Publications
- Open Access
- 2 October 2021
- Published by Journal of Pure and Applied Microbiology in Journal of Pure and Applied Microbiology
- Vol. 15 (4) , 2103-2116
Molecular Docking of Anti Helicobacter pylori Antibiotics and Proton Pump Inhibitor: A Single Center Survey
Helicobacter pylorus (H. pylori) is a deadly bacterium responsible for significant worldwide Gastric Cancer (GC) related mortality. The present study aimed to screen all the anti-microbial drugs used to eradicate H .pylori infection and to identify the most efficient drug by using computational methods through molecular docking analysis. The 3-D structure of protein chorismate synthase of H. pylori was downloaded from the Protein data bank (PDB) online browser. The x-ray crystallography structures of 13 common drugs used against H.pylori infection were also downloaded from the drug bank. We screened all 13 common drugs through molecular docking to know the most efficient binding interaction between the diverse ligand-protein complexes. The results were further compared with clinical survey data from the patients with diverse gastrointestinal H. pylori infected cases. Among the screened compounds, by in-silico approach we found that fluoroquinolone (FLRQ) and tetracycline (TET) manifested more significant interactions with chorismate synthase (CS) protein along with binding energies of -9.2 and -8.1 kcal/mole respectively. Further, the drugs were also corroborated with the survey data from patients with varied gastrointestinal disorders in our study. With this computational study, we could find FLRQ and TET may be the most efficient drug for H. pylori treatment, which can be tried in case of anti H. Pylori treatment failure due to resistance. Hence, effective inter-analysis between the experimental and computational approaches is crucial to build up a strong inhibitor.
- 2 October 2021
- Published by Journal of Pure and Applied Microbiology in Journal of Pure and Applied Microbiology
- Vol. 15 (4) , 2103-2116
Open AccessMolecular Docking of Anti Helicobacter pylori Antibiotics and Proton Pump Inhibitor: A Single Center Survey
Helicobacter pylorus (H. pylori) is a deadly bacterium responsible for significant worldwide Gastric Cancer (GC) related mortality. The present study aimed to screen all the anti-microbial drugs used to eradicate H .pylori infection and to identify the most efficient drug by using computational methods through molecular docking analysis. The 3-D structure of protein chorismate synthase of H. pylori was downloaded from the Protein data bank (PDB) online browser. The x-ray crystallography structures of 13 common drugs used against H.pylori infection were also downloaded from the drug bank. We screened all 13 common drugs through molecular docking to know the most efficient binding interaction between the diverse ligand-protein complexes. The results were further compared with clinical survey data from the patients with diverse gastrointestinal H. pylori infected cases. Among the screened compounds, by in-silico approach we found that fluoroquinolone (FLRQ) and tetracycline (TET) manifested more significant interactions with chorismate synthase (CS) protein along with binding energies of -9.2 and -8.1 kcal/mole respectively. Further, the drugs were also corroborated with the survey data from patients with varied gastrointestinal disorders in our study. With this computational study, we could find FLRQ and TET may be the most efficient drug for H. pylori treatment, which can be tried in case of anti H. Pylori treatment failure due to resistance. Hence, effective inter-analysis between the experimental and computational approaches is crucial to build up a strong inhibitor.
- 15 September 2020
- Published by Egyptian Knowledge Bank in Microbes and Infectious Diseases
Liver Cirrhosis and Concomitant Gastric Helicobacter Pylori Infection
Background: Cirrhosis of liver causes a lot of morbidities and mortalities. Around one third Indians had Helicobacter Pylori (H.Pylori) infection, whose effect in disease course of cirrhosis is poorly defined. Therefore this study was undertaken with an aim to find out variable effects of Helicobacter Pylori infection in cirrhotic patients. Methods: This cross-sectional, observational, open labeled, non interventional, single centered study was carried out in the Department of Gastroenterology of Institute of Medical Sciences (I.M.S.) & SUM Hospital, Bhubaneswar in between January 2018 and December 2019. Consecutive cirrhotic cases attending the hospital were enrolled in the study, after undergoing biochemical, radiological and endoscopic evaluation. All of them also subjected to rapid urease test (RUT) to rule out Helicobacter Pylori infection. Results: Total 864 cirrhotic cases were included in this study, amongst which male outnumbered female. Mean age of presentation was 48.24±10.77 years. Alcohol was the most common etiology. Around 57.4% of cirrhosis cases had Helicobacter Pylori infection. 70.96% of alcoholic liver disease (ALD) and 50% of cryptogenic cirrhosis cases had Helicobacter Pylori infection, whereas none of chronic Hepatitis B virus (HBV) related cirrhotic had rapid urease test (RUT) positivity. Cases with Helicobacter Pylori infection presented early and had relatively higher prevalence of higher grade of Esophageal Varix, Portal hypertensive Gastropathy, Duodenal ulcer, Gastric Antral Vascular Ectasia, Gastroesophageal Varix II compared to cases without Helicobacter Pylori infection. The prognostic score such as model for end stage liver disease (MELD) was relatively higher in cases without Helicobacter Pylori infection compared to cases with Helicobacter Pylori infection. Conclusion: In our study, we found most of cirrhotic cases had alcoholic liver disease and were male. Around half of cases had Helicobacter Pylori infection and earlier presentation. Although the cases with Helicobacter Pylori infection had relatively higher endoscopic severity but had lower prognostic score compared to cases without Helicobacter Pylori infection, which should be validated in future by further studies.
- 15 September 2020
- Published by Egyptian Knowledge Bank in Microbes and Infectious Diseases
Liver Cirrhosis and Concomitant Gastric Helicobacter Pylori Infection
Background: Cirrhosis of liver causes a lot of morbidities and mortalities. Around one third Indians had Helicobacter Pylori (H.Pylori) infection, whose effect in disease course of cirrhosis is poorly defined. Therefore this study was undertaken with an aim to find out variable effects of Helicobacter Pylori infection in cirrhotic patients. Methods: This cross-sectional, observational, open labeled, non interventional, single centered study was carried out in the Department of Gastroenterology of Institute of Medical Sciences (I.M.S.) & SUM Hospital, Bhubaneswar in between January 2018 and December 2019. Consecutive cirrhotic cases attending the hospital were enrolled in the study, after undergoing biochemical, radiological and endoscopic evaluation. All of them also subjected to rapid urease test (RUT) to rule out Helicobacter Pylori infection. Results: Total 864 cirrhotic cases were included in this study, amongst which male outnumbered female. Mean age of presentation was 48.24±10.77 years. Alcohol was the most common etiology. Around 57.4% of cirrhosis cases had Helicobacter Pylori infection. 70.96% of alcoholic liver disease (ALD) and 50% of cryptogenic cirrhosis cases had Helicobacter Pylori infection, whereas none of chronic Hepatitis B virus (HBV) related cirrhotic had rapid urease test (RUT) positivity. Cases with Helicobacter Pylori infection presented early and had relatively higher prevalence of higher grade of Esophageal Varix, Portal hypertensive Gastropathy, Duodenal ulcer, Gastric Antral Vascular Ectasia, Gastroesophageal Varix II compared to cases without Helicobacter Pylori infection. The prognostic score such as model for end stage liver disease (MELD) was relatively higher in cases without Helicobacter Pylori infection compared to cases with Helicobacter Pylori infection. Conclusion: In our study, we found most of cirrhotic cases had alcoholic liver disease and were male. Around half of cases had Helicobacter Pylori infection and earlier presentation. Although the cases with Helicobacter Pylori infection had relatively higher endoscopic severity but had lower prognostic score compared to cases without Helicobacter Pylori infection, which should be validated in future by further studies.